У нас вы можете посмотреть бесплатно KANDLELIT-001: MK-1084 monotherapy in KRAS G12C- mutated advanced solid tumors или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Matteo Simonelli, MD, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy, discusses the results of the KANDLELIT-001 study (NCT05067283), a Phase I trial evaluating the safety and efficacy of MK-1084 monotherapy in patients with KRAS G12C-mutated advanced solid tumors, highlighting that the drug was well tolerated with promising anti-tumor activity, particularly in hepatobiliary cancer and pancreatic adenocarcinoma, with an overall response rate of 31% and disease control rate of 75%. Dr Simonelli notes that the most common treatment-related adverse events were liver enzyme elevation, low-grade diarrhea, fatigue, and nausea. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.